Trial Profile
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Efatutazone (Primary) ; Paclitaxel
- Indications Thyroid cancer
- Focus Therapeutic Use
- 25 Apr 2023 Status changed from active, no longer recruiting to completed.
- 27 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2018 Status changed from suspended to recruiting.